The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Li, Xiaojun ^a   Yang, Chunyan ^a   Wang, Xiaoqiang ^a   Zhang, Jian ^a   Zhang, Ruipeng ^a   Liu, Ruiting ^a  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Colorectal cancer; miR 25; Prognosis; Real time PCR

Indexed keywords

MICRORNA; MICRORNA 25; UNCLASSIFIED DRUG; MIRN25 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; COLON; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; YOUNG ADULT; AGED; COLORECTAL NEOPLASMS; DISEASE COURSE; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME;

AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84888259658     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0781-7     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62(1):10-29. doi: 10.3322/caac.20138.
2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366-78. doi: 10.3322/caac.20038.
3. Deng SX, An W, Gao J, Yin J, Cai QC, Yang M, et al. Factors influencing diagnosis of colorectal cancer: a hospital-based survey in China. J Dig Dis. 2012;13(10):517-24. doi: 10.1111/j.1751-2980.2012.00626.x.
4. Chen HM, Weng YR, Jiang B, Sheng JQ, Zheng P, Yu CG, et al. Epidemiological study of colorectal adenoma and cancer in symptomatic patients in China between 1990 and 2009. J Dig Dis. 2011;12(5):371-8. doi: 10.1111/j.1751-2980.2011.00531.x.
5. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41. doi: 10.3322/caac.21149.
6. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57(3):168-85. (Pubitemid 46798625)
7. Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3(3):83-92.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-33. doi: 10.1016/j.cell.2009.01.002.
9. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol. 2004;2(11):e363. doi: 10.1371/journal.pbio.0020363. (Pubitemid 40280484)
10. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, et al. A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 2004;18(10):1165-78. doi: 10.1101/gad.1184704. (Pubitemid 38669037)
11. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66. doi: 10.1038/nrc1997. (Pubitemid 44629897)
12. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257-61. doi: 10.1073/pnas.0510565103. (Pubitemid 43271657)
13. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012;12:505. doi: 10.1186/1471-2407-12-505.
14. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol WJG. 2009;15(17):2089-96.
15. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29. doi: 10.1186/1476-4598-5-29. (Pubitemid 44264064)
16. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34(4):1069-75.
17. Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012;33(1):220-5. doi: 10.1093/carcin/bgr245.
18. Liu L, Chen L, Xu Y, Li R, Du X. microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400(2):236-40. doi: 10.1016/j.bbrc.2010.08.046.
19. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b ~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3(117):ra29. doi: 10.1126/scisignal.2000594.
20. Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA expression in pediatric brain tumors. Pediatr Blood Cancer. 2011;56(2):211-6. doi: 10.1002/pbc.22723.
21. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272-86. doi: 10.1016/j.ccr.2008.02.013. (Pubitemid 351318375)
22. Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010;23(12):1577-82. doi: 10.1038/modpathol.2010.152.
23. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009;100(7):1234-42. doi: 10.1111/j.1349-7006.2009.01164.x.
24. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-74. doi: 10.1038/nrg3074.
25. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522-31. doi: 10.1038/nrg1379. (Pubitemid 38868508)
26. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4(9):1179-84. (Pubitemid 41365387)
27. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849-64. doi: 10.1038/nrc3166.
28. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res. 2007;619(1-2):30-7. doi: 10.1016/j.mrfmmm.2006. 12.006. (Pubitemid 46602445)
29. Zhao H, Wang Y, Yang L, Jiang R, Li W. miR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2013;. doi: 10.1007/s11010-013-1829-x.
30. Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27(2):594-8. doi: 10.3892/or 2011.1530.
31. Xu JY, Yang LL, Ma C, Huang YL, Zhu GX, Chen QL. MiR-25-3p attenuates the proliferation of tongue squamous cell carcinoma cell line Tca8113. Asian Pac J Trop Biomed. 2013;6(9):743-7. doi: 10.1016/S1995-7645(13)60130-3.
32. Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis. 2010;44(3):191-7. doi: 10.1016/j.bcmd.2009.12.010.
33. Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012;421(4):640-5. doi: 10.1016/j.bbrc.2012.03.048.